常规疗法联合低分子肝素钙治疗老年不稳定型心绞痛疗效观察被引量：1

导出

摘要目的 :观察常规疗法联合低分子肝素钙治疗老年不稳定型心绞痛 (UAP)的临床疗效。方法 :将 5 6例老年 UAP患者随机分成对照组 2 8例和观察组 2 8例 ,对照组采用常规疗法 ,观察组在常规疗法基础上加用低分子肝素钙 ,疗程均为 1周。观察心绞痛发作次数、1 2导联常规心电图 ST段压低数值总和 (Σ ST)及副作用发生率。结果 :观察组治疗后心绞痛发作次数减少 ,Σ ST明显改善 ,与对照组比较差异有统计学意义 (P <0 .0 5 ) ;观察组治疗期间无急性心肌梗死 (AMI)及死亡发生 ,对照组发生 AMI 2例 ,严重心律失常 6例 ,两组比较差异有统计学意义 (P <0 .0 5 ) ,观察组治疗前后血小板、出血时间、凝血酶原时间、凝血时间、血浆纤维蛋白原均无明显改变 (P >0 .0 5 ) ,且无出血并发症。结论 :常规疗法联合低分子肝素钙治疗老年 U AP效果好 ,可避免 AMI发生 ,且安全。

作者黄彩念黄凯

机构地区广西平果县人民医院心内科广西心血管病研究所

出处《广西医科大学学报》 CAS 2004年第2期218-219,共2页 Journal of Guangxi Medical University

关键词低分子肝素钙心绞痛不稳定型老年

分类号 R542.22 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1Braunwald著.心脏病学.第5版.陈灏珠主译.北京:人民卫生出版社,2000.1 203.
2Kikeboen KA. Unstable angina pectoris pathogeoesis tr-eatment and prognosis.Tidsskr Nor Laegeforen,1995,115(27):3 376.
3陈修,陈维洲,曾贵云主编.心血管药理学.第2版.北京:人民卫生出版社,1996.565-566.
4Clinical Collaborative Study Group of Low Molecular Weight Heparin (Correspondent: HU Dayi, XU Juntang. Beijing Red Cross Chaoyang Hospital, Beijing University of Medical Sciences, Beijing 100020, China).不稳定性心绞痛、急性非Q波心肌梗死不同抗栓疗法的对比研究[J].中华心血管病杂志,2000,28(1):18-21. 被引量：172
5李娅莉,李晓春.不稳定性心绞痛的治疗进展[J].临床荟萃,2001,16(1):38-39. 被引量：15
6Kauw FH,Cleophas TJ,kalmansohn RB.Low molecular-weight heparins better than unfractionated heparin in unstable coronary artery disease? Unstable angianpector-is/non-Q wave infarction a partly outpatient clinic condition? Int J Clin Pharmacol Ther,1998,36(7):392-397.

二级参考文献14

1[1]Rakov AL,Ianshin VL,Makarenko AS,et al.Role of thrombolytic therapy in the treatment of patients with unstable angina.Klin Med Mosk,1998,76:27-29
2[2]Itoh T,Nonogi H,Miyazaki S,et al.Does coronary artery morphology predict favorable results of intracoronary thrombolysis in patients with unstable angina pectoris Jpn Circ J,1999,63:13-18
3[3]Hamm CW.progress in the diagnosis of unstable angina and perspectives for treatment.Eur Heart J,1998,19:45-50
4[4]Goa KL,Noble S.Eptifibatide:a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.Drugs,1999,57:439-462
5[5]International,randomized,controlled trial of lamifiban)aplatelet glycoprotein Ⅱb/Ⅲa inhibitor),heparin,of both in unstable angina,The PARAGON Investigators,platelet Ⅱb/Ⅲa Antagonism for the Reduction of Acute coronary Syndrome events in a Global organization Network,circulation,1998,97:2386-2395
6[6]Kauw FH,Cleophas TJ,Kalmansohn RB,Low molecular weight heparins better than unfractionated heparin in unstble coronary artery disease? unstable angian pectoris/non-Q wave infaetion a partly outpatient clinic condition?Imt J Clin pharmacol Ther,1998,36:392-397
7[7]Demers C.ESSENCE trial results:breaking new ground.Efficacy and safety of subcutaneous Enoxaparin in Non-Q wave coronary Events.Can J cardiol,1998,14:15-19
8[8]Godoy I,Herrera C,Zapata C,et al.Comparison of low molecular weight heparin and unfractionated heparin in treatment of nustable angina,Rev Med Chil,1998,126:259-264
9[9]Turpie AG.Management of acute coronary syndromes with low molecular weight heparin:TIMI11A and11B.Can J cardiol,1998,14:20-23
10[10] Bittl JA,Strony J,Brinker JA,et al.Treatment with bibalirudin(Hirulog)as compared with heparin during coronary angioplasty for unstable or postinfarvtion angina.Hirulog Angioplasty study Investigators.N Engl J Med,1995,333:764-769